08Dec 2023
Overall Survival From Tebentafusp Versus Nivolumab Plus Ipilimumab in First Line Metastatic Uveal Melanoma

Overall Survival From Tebentafusp Versus Nivolumab Plus Ipilimumab in First Line Metastatic Uveal Melanoma

Tebentafusp demonstrated superior overall survival (OS) compared to pembrolizumab in a Phase 3 trial for untreated metastatic uveal melanoma (mUM). In a propensity score analysis, tebentafusp was compared to nivolumab plus ipilimumab (N+I) from a different trial. Adjusted OS favored tebentafusp, with a hazard ratio (HR) of 0.52 and a 1-year OS rate of 73% versus 50% for N+I. Sensitivity analyses confirmed the consistent superiority of tebentafusp. These findings further support tebentafusp as the standard of care for untreated mUM patients.

  • #oncology

Like

Save

Share